



## **Nova Mentis Announces Symbol Change on OTC Market to NMLSF**

**Vancouver, British Columbia – February 24, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”)**, a leader in the development of psilocybin and other psychedelic compounds with broad cognitive, behavioral, and peripheral physiologic effects, announces that, effective February 25, 2021, its common shares, previously listed for trading on the OTC Pink Market in the United States under the symbol "LIBFF", are to commence trading on the OTC Pink Market under the symbol "NMLSF". The Company's common shares will continue to trade on the Canadian Securities Exchange under the symbol "NOVA" and on the Frankfurt Stock Exchange under the symbol “HN3Q”.

Nova Mentis has applied to list its common shares on the OTCQB Market and expects approval in the near future. The OTCQB Venture Market is operated by the OTC Markets Group Inc. an established financial market in the United States.

### **About Nova Mentis Life Science Corp.**

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company that is focused on the emerging field of serotonergic psychedelic medicine, such as psilocybin and its related tryptamine derivatives. The Company is a global leader in this field by integrating the latest state-of-the-art medical and scientific technology into its drug development program. The goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD).

For further information on the Company, please visit <https://www.novamentis.ca> or email [info@novamentis.ca](mailto:info@novamentis.ca).

### **On Behalf of the Board**

*Will Rascan, President & CEO*  
Nova Mentis Life Science Corp.

Phone: 778-819-0244  
Toll Free: 1-833-542-5323

Twitter: @novamentislsc  
Instagram: @novamentislsc



Facebook: @novamentislsc

*Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.*